Antonio Poerio

756 total citations
23 papers, 365 citations indexed

About

Antonio Poerio is a scholar working on Hematology, Genetics and Pulmonary and Respiratory Medicine. According to data from OpenAlex, Antonio Poerio has authored 23 papers receiving a total of 365 indexed citations (citations by other indexed papers that have themselves been cited), including 9 papers in Hematology, 6 papers in Genetics and 6 papers in Pulmonary and Respiratory Medicine. Recurrent topics in Antonio Poerio's work include Chronic Myeloid Leukemia Treatments (9 papers), Chronic Lymphocytic Leukemia Research (5 papers) and Eosinophilic Disorders and Syndromes (5 papers). Antonio Poerio is often cited by papers focused on Chronic Myeloid Leukemia Treatments (9 papers), Chronic Lymphocytic Leukemia Research (5 papers) and Eosinophilic Disorders and Syndromes (5 papers). Antonio Poerio collaborates with scholars based in Italy and Uganda. Antonio Poerio's co-authors include Maurizio Zompatori, Giovanni Martinelli, Marilina Amabile, Michele Baccarani, Francesca Palandri, Ilaria Iacobucci, Simona Soverini, Giuseppe Saglio, G. Rosti and Fausto Castagnetti and has published in prestigious journals such as Journal of Clinical Oncology, International Journal of Radiation Oncology*Biology*Physics and Annals of Oncology.

In The Last Decade

Antonio Poerio

21 papers receiving 359 citations

Peers

Countries citing papers authored by Antonio Poerio

Since Specialization

Citations

This map shows the geographic impact of Antonio Poerio's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Antonio Poerio with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Antonio Poerio more than expected).

Fields of papers citing papers by Antonio Poerio

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Antonio Poerio. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Antonio Poerio. The network helps show where Antonio Poerio may publish in the future.

Co-authorship network of co-authors of Antonio Poerio

This figure shows the co-authorship network connecting the top 25 collaborators of Antonio Poerio. A scholar is included among the top collaborators of Antonio Poerio based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Antonio Poerio. Antonio Poerio is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

#	Work	Indexed citations
1	Clinical Images: Osteomyelitis complicating uncommon tophaceous gout: a case study with genetic findings 2024 ·ACR Open Rheumatology ·Matteo Colina, (unknown), Antonio Poerio	0
2	Diagnosis of interstitial lung disease (ILD) secondary to systemic sclerosis (SSc) and rheumatoid arthritis (RA) and identification of ‘progressive pulmonary fibrosis’ using chest CT: a narrative review 2023 ·Clinical and Experimental Medicine ·Antonio Poerio, (unknown), Maurizio Zompatori	8
3	Correction to: Diagnosis of interstitial lung disease (ILD) secondary to systemic sclerosis (SSc) and rheumatoid arthritis (RA) and identification of ‘progressive pulmonary fibrosis’ using chest CT: a narrative review 2023 ·Clinical and Experimental Medicine ·Antonio Poerio, (unknown), Maurizio Zompatori	0
4	Evolution of COVID-19 Pulmonary Fibrosis–Like Residual Changes Over Time — Longitudinal Chest CT up to 9 Months After Disease Onset: a Single-Center Case Series 2022 ·SN Comprehensive Clinical Medicine ·Antonio Poerio, (unknown), (unknown), (unknown), (unknown), (unknown), (unknown), Maurizio Zompatori, Rodolfo Ferrari	6
5	Lung ultrasound features predict admission to the neonatal intensive care unit in infants with transient neonatal tachypnoea or respiratory distress syndrome born by caesarean section 2020 ·European Journal of Pediatrics ·Antonio Poerio, Silvia Galletti, (unknown), Silvia Martini, (unknown), (unknown), Francesco Raimondi, Maurizio Zompatori, Luigi Corvaglia, Arianna Aceti	30
6	Halo, Reversed Halo, or Both? Atypical Computed Tomography Manifestations of Coronavirus Disease (COVID-19) Pneumonia: The “Double Halo Sign” 2020 ·Korean Journal of Radiology ·Antonio Poerio, (unknown), (unknown), (unknown), (unknown), Maurizio Zompatori	8
7	New disappearance of complicated atheromatous plaques on rechallenge with PD-1/PD-L1 axis blockade in non-small cell lung cancer patient: follow up of an unexpected event 2020 ·Therapeutic Advances in Medical Oncology ·Giuseppe Lamberti, Francesco Gelsomino, Stefano Brocchi, Antonio Poerio, Barbara Melotti, Francesca Sperandi, Mauro Gargiulo, Claudio Borghi, Michelangelo Fiorentino, Andrea Ardizzoni	9
8	Organizing pneumonia after pancreatic cancer treatment with nab-paclitaxel and gemcitabine: a case report 2018 ·BJR\|case reports ·Francesca Comito, Elisa Grassi, Antonio Poerio, (unknown), Lucia Calculli, Maurizio Zompatori, Claudio Ricci, Riccardo Casadei, Mariacristina Di Marco	4
9	Programmed death-1 inhibition and atherosclerosis: can nivolumab vanish complicated atheromatous plaques? 2017 ·Annals of Oncology ·Francesco Gelsomino, Michelangelo Fiorentino, Maurizio Zompatori, Antonio Poerio, Barbara Melotti, Francesca Sperandi, Mauro Gargiulo, Claudio Borghi, Andrea Ardizzoni	24
10	Saber-sheath trachea as a marker of severe airflow obstruction in chronic obstructive pulmonary disease 2013 ·La radiologia medica ·Federica Ciccarese, Antonio Poerio, Silvia Stagni, Domenico Attinà, Luca Fasano, (unknown), Maria Letizia Bacchi Reggiani, Maurizio Zompatori	16
11	The response to imatinib and interferon- is more rapid than the response to imatinib alone: a retrospective analysis of 495 Philadelphia-positive chronic myeloid leukemia patients in early chronic phase 2010 ·Haematologica ·Francesca Palandri, Fabio Castagnetti, Ilaria Iacobucci, Giovanni Martinelli, Marilina Amabile, Gabriele Gugliotta, Antonio Poerio, Nicoletta Testoni, (unknown), (unknown), Monica Crugnola, Giovanna Rege‐Cambrin, B. Martino, Ivana Pierri, Franco Radaelli, Giorgina Specchia, Fabrizio Pane, Giuseppe Saglio, Gianantonio Rosti, Michele Baccarani	32
12	Philadelphia-positive acute lymphoblastic leukemia patients already harbor BCR-ABL kinase domain mutations at low levels at the time of diagnosis 2010 ·Haematologica ·Simona Soverini, Alessandro Vitale, Antonio Poerio, Alessandra Gnani, Sabrina Colarossi, Ilaria Iacobucci, Giuseppe Cimino, L Elia, Annalisa Lonetti, Marco Vignetti, Stefania Paolini, Giovanna Meloni, (unknown), Cristina Papayannidis, Marilina Amabile, Anna Guarini, Michele Baccarani, Giovanni Martinelli, R. Foà	64
13	Efficacy and safety of nilotinib 800 mg daily in early chronic phase Ph+ chronic myeloid leukemia: Results of a phase II trial at 2 years. 2010 ·Journal of Clinical Oncology ·G. Rosti, Fausto Castagnetti, Francesca Palandri, Antonio Poerio, Simona Soverini, Massimo Breccia, (unknown), Giovanni Martinelli, Michele Baccarani, Giuseppe Saglio	6
14	GENOME-WIDE SCREENING OF CHRONIC MYELOID LEUKEMIA PATIENTS BY SNP ARRAYS: ALTERATIONS ASSOCIATED WITH DISEASE PROGRESSION 2009 ·Haematologica ·Sabrina Colarossi, Alessandra Gnani, Simona Soverini, Fabio Castagnetti, G Marzocchi, Simona Luatti, Annalisa Astolfi, Serena Formica, Ilaria Iacobucci, Annalisa Lonetti, Francesca Palandri, Antonio Poerio, Marilina Amabile, (unknown), Andrea Pession, Nicoletta Testoni, Michele Baccarani, Giovanni Martinelli	2
15	Thyrosin kinase inhibitors: nilotinib 2009 ·Fausto Castagnetti, Francesca Palandri, Gabriele Gugliotta, Antonio Poerio, Marilina Amabile, Simona Soverini, Giovanni Martinelli, Michele Baccarani, Gianantonio Rosti	1
16	Pancreatic enzyme elevation in chronic myeloid leukemia patients treated with nilotinib after imatinib failure 2009 ·Haematologica ·Francesca Palandri, Fabio Castagnetti, Simona Soverini, Antonio Poerio, Gabriele Gugliotta, Simona Luatti, Marilina Amabile, Giovanni Martinelli, G. Rosti, Michele Baccarani	26
17	Molecular responses with nilotinib 800 mg daily as first-line treatment of chronic myeloid leukemia in chronic phase: Results of a phase II trial of the GIMEMA CML WP 2009 ·Journal of Clinical Oncology ·Giovanni Martinelli, Fausto Castagnetti, Antonio Poerio, Massimo Breccia, Francesca Palandri, Giuliana Alimena, Fabrizio Pane, Giuseppe Saglio, Michele Baccarani, Gianantonio Rosti	6
18	Front-line treatment of Philadelphia positive chronic myeloid leukemia with imatinib and interferon- : 5-year outcome 2008 ·Haematologica ·Francesca Palandri, Ilaria Iacobucci, Fausto Castagnetti, Nicoletta Testoni, Antonio Poerio, Marilina Amabile, Massimo Breccia, Tamara Intermesoli, F. Iuliano, Giovanna Rege‐Cambrin, Mario Tiribelli, María Angélica Miglino, Fabrizio Pane, Giuseppe Saglio, Giovanni Martinelli, G. Rosti, Michele Baccarani, (unknown)	38
19	Impact of age on the outcome of patients with chronic myeloid leukemia in late chronic phase: results of a phase II study of the GIMEMA CML Working Party 2007 ·Haematologica ·G. Rosti, Ilaria Iacobucci, (unknown), Fausto Castagnetti, Marilina Amabile, Daniela Cilloni, Antonio Poerio, Simona Soverini, Francesca Palandri, Giovanna Rege Cambrin, F. Iuliano, Giuliana Alimena, Roberto Latagliata, Nicoletta Testoni, F. Pane, Giuseppe Saglio, Michele Baccarani, Giovanni Martinelli	39
20	Cyclooxygenase-2 (COX-2) expression in locally advanced cervical cancer patients undergoing chemoradiation plus surgery 2002 ·International Journal of Radiation OncologyBiologyPhysics ·Gabriella Ferrandina, Franco O. Ranelletti, Francesco Legge, Libero Lauriola, Antonio Poerio, Gianfranco Zannoni, D. Smaniotto, Pasquale Alessandro Margariti, Gabriella Macchia, Giovanni Scambia	22

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact